Literature DB >> 19997114

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways.

A-M Cleton-Jansen, J K Anninga, I H Briaire-de Bruijn, S Romeo, J Oosting, R M Egeler, H Gelderblom, A H M Taminiau, P C W Hogendoorn.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19997114      PMCID: PMC2795446          DOI: 10.1038/sj.bjc.6605482

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Correction to: British Journal of Cancer (2009) 101, 1909–1918; doi:10.1038/sj.bjc.6605405 Upon publication of this paper in the last issue, an error was spotted in the clinical data in Table 1 – Chip number IB54 was incorrectly listed twice, when in the second instance it should have been referred to as IB60. The correct data are now shown below.
Table 1

Clinical data

Sample ID Chip no. Type Age (years) Gender Subtype Adj. CT Chemo response Overall survival Metastasis
L1370IB10Osteosarcoma14MaleHG conv.PLAGoodGoodLung
L1372IB12Osteosarcoma10MaleHG conv.APGoodGood0
L1382IB14Osteosarcoma16MaleTel.PIAPoorPoorLung
L1385IB16Osteosarcoma13FemaleTel.MAPoorPoorLung
L1016IB19Osteosarcoma4MaleHG conv.APPoorGood0
L2620IB21Osteosarcoma16MaleHG conv.APPoorPoorLung+bone
L1375IB22Osteosarcoma8MaleHG conv.APPoorGoodLocal
L428IB32Osteosarcoma16MaleHG conv.APPoorGoodLung
L436IB33Osteosarcoma18MaleHG conv.MAPoorGood0
L432IB34Osteosarcoma17MaleHG conv.APPoorPoorLung
L361IB35Osteosarcoma16FemaleHG conv.APPoorGood0
L1368IB36Osteosarcoma10FemaleHG conv.PIAGoodGood0
L1376IB37Osteosarcoma9FemaleHG conv.APGoodGood0
L1386IB38Osteosarcoma12FemaleHG conv.APPoorPoorLung
L2702IB39Osteosarcoma16MaleHG conv.APGoodPoorLung
L2302IB40Osteosarcoma19FemaleHG conv.APPoorGood0
L2296IB41Osteosarcoma16MaleHG conv.APGoodPoorLung+else
L2295IB42Osteosarcoma40FemaleHG conv.APPoorGood0
L2611IB43Osteosarcoma20FemaleHG conv.APGoodGood0
L2300IB44Osteosarcoma13MaleHG conv.APGoodGood0
L2294IB45Osteosarcoma17FemaleHG conv.APPoorGood0
L2290IB46Osteosarcoma36MaleHG conv.APPoorPoorLocal
L2301IB47Osteosarcoma25MaleHG conv.APPoorPoorLung+else
L2281IB48Osteosarcoma17MaleHG conv.APPoorPoorLung
L2289IB54Osteosarcoma11MaleHG conv.APPoorGood0
L578IB55Osteoblastoma22Male   Relapse 
L579IB56aOsteoblastoma22Male   Relapse 
L580IB57Osteoblastoma13Male   Remission 
L581IB58Osteoblastoma16Male   Remission 
L601IB59Osteoblastoma44Male   Remission 
          
FMSC-OB-diffIB49Osteoblasts       
MSC1-OB-diffIB50Osteoblasts       
220-OB-diffIB51Osteoblasts       
240-OB-diffIB52Osteoblasts       
MSC2-OB-diffIB53Osteoblasts       
MSC1IB60MSC       
MSC2IB61MSC       
C220RIB62MSC       
C240RIB63MSC       
FMSCIB64MSC       

Abbreviations: Adj. CT=adjuvant chemotherapy; AP=adriamycin and cisplatinum; HG=high grade; HG conv.=high-grade conventional; MA=methotrexate and adriamycin; MSC=mesenchymal stem cell; OB=osteoblastoma; PIA=cisplatinum, ifosfamide and adriamycin; Tel.=telangiectatic.

IB56 is the recurrence from IB55.

  13 in total

1.  Osteosarcoma cells differentiate into phenotypes from all three dermal layers.

Authors:  Scott Russinoff; Sara Miran; Ashok L Gowda; Paul A Lucas
Journal:  Clin Orthop Relat Res       Date:  2011-06-16       Impact factor: 4.176

2.  A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.

Authors:  Luke A Wittenburg; Andrey A Ptitsyn; Douglas H Thamm
Journal:  J Cell Biochem       Date:  2012-03       Impact factor: 4.429

Review 3.  RecQ Helicase Somatic Alterations in Cancer.

Authors:  Megha K Thakkar; Jamie Lee; Stefan Meyer; Vivian Y Chang
Journal:  Front Mol Biosci       Date:  2022-06-15

4.  Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.

Authors:  Bekim Sadikovic; Paul Thorner; Susan Chilton-Macneill; Jeff W Martin; Nilva K Cervigne; Jeremy Squire; Maria Zielenska
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

5.  mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts.

Authors:  Marieke L Kuijjer; Heidi M Namløs; Esther I Hauben; Isidro Machado; Stine H Kresse; Massimo Serra; Antonio Llombart-Bosch; Pancras C W Hogendoorn; Leonardo A Meza-Zepeda; Ola Myklebost; Anne-Marie Cleton-Jansen
Journal:  BMC Med Genomics       Date:  2011-09-20       Impact factor: 3.063

6.  Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy.

Authors:  Marieke L Kuijjer; Brendy E W M van den Akker; Riet Hilhorst; Monique Mommersteeg; Emilie P Buddingh; Massimo Serra; Horst Bürger; Pancras C W Hogendoorn; Anne-Marie Cleton-Jansen
Journal:  BMC Med Genomics       Date:  2014-01-21       Impact factor: 3.063

7.  β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells.

Authors:  Sajida Piperdi; Lukas Austin-Page; David Geller; Manpreet Ahluwalia; Sarah Gorlick; Jonathan Gill; Amy Park; Wendong Zhang; Nan Li; So Hak Chung; Richard Gorlick
Journal:  Sarcoma       Date:  2012-10-18

8.  IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.

Authors:  Marieke L Kuijjer; Elisabeth F P Peterse; Brendy E W M van den Akker; Inge H Briaire-de Bruijn; Massimo Serra; Leonardo A Meza-Zepeda; Ola Myklebost; A Bassim Hassan; Pancras C W Hogendoorn; Anne-Marie Cleton-Jansen
Journal:  BMC Cancer       Date:  2013-05-20       Impact factor: 4.430

9.  Manipulation therapy prior to diagnosis induced primary osteosarcoma metastasis--from clinical to basic research.

Authors:  Jir-You Wang; Po-Kuei Wu; Paul Chih-Hsueh Chen; Chuen-Chuan Yen; Giun-Yi Hung; Cheng-Fong Chen; Shih-Chieh Hung; Shih-Fen Tsai; Chien-Lin Liu; Tain-Hsiung Chen; Wei-Ming Chen
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

10.  Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.

Authors:  Ene Reimann; Sulev Kõks; Xuan Dung Ho; Katre Maasalu; Aare Märtson
Journal:  Hum Genomics       Date:  2014-12-11       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.